In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price ...

The share price in Arrowhead Pharmaceuticals Inc. jumped by more than 48% in the two months since it hit its lowest value of the past year. On Oct. 10, ...

It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have added about 4.9% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Quantbot Technologies LP bought a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) during the 3rd quarter, according to its most recent filing with the Securities and ...

Not exactly known for its dealmaking, Sarepta Therapeutics has thrown down a massive wad of cash to work with Arrowhead ...

Rachel Potter and coauthors from Sarepta Therapeutics injected DMD rats with delandistrogene moxeparvovec and then assessed ...

Learn more about whether BioMarin Pharmaceutical Inc. or Exact Sciences Corporation is a better investment based on AAII's A+ ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and decreased the price ...

Employers are grappling with the limits of both traditional and innovative payment models for coverage in trying to offer ...

Despite hotly debated biomarkers and failed or delayed confirmatory trials, the accelerated approval program has a track ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2024 (the ...

On Wednesday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $137.94 which represents a slight increase of $7.44 or 5.70% from the prior close of $130.5. The stock opened ...